Neuroprotective and Anti-inflammatory Properties of a Coffee Component in the MPTP Model of Parkinson’s Disease

[1]  J. Stock,et al.  Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson’s disease , 2012, Neurochemistry International.

[2]  R. Sinha,et al.  Association of coffee drinking with total and cause-specific mortality. , 2012, The New England journal of medicine.

[3]  D. German,et al.  Apoptosis Signal-Regulating Kinase 1 Mediates MPTP Toxicity and Regulates Glial Activation , 2012, PloS one.

[4]  J. Stock,et al.  Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease. , 2011, Future medicinal chemistry.

[5]  E. Masliah,et al.  Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model , 2011, The Journal of Neuroscience.

[6]  Hee-Sun Kim,et al.  α-Synuclein Activates Microglia by Inducing the Expressions of Matrix Metalloproteinases and the Subsequent Activation of Protease-Activated Receptor-1 , 2010, The Journal of Immunology.

[7]  Laurie A Andrews,et al.  Decaffeinated Coffee and Nicotine-Free Tobacco Provide Neuroprotection in Drosophila Models of Parkinson's Disease through an NRF2-Dependent Mechanism , 2010, The Journal of Neuroscience.

[8]  N. Lunet,et al.  Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. , 2010, Journal of Alzheimer's disease : JAD.

[9]  M. Kivipelto,et al.  Caffeine as a protective factor in dementia and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[10]  V. Perry,et al.  Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.

[11]  D. D. Di Monte,et al.  Serine 129 Phosphorylation Reduces the Ability of α-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2A in Vitro and in Vivo , 2010, The Journal of Biological Chemistry.

[12]  Hyoung-Gon Lee,et al.  Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells , 2010, Neuroscience Letters.

[13]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[14]  S. Shenolikar,et al.  From promiscuity to precision: protein phosphatases get a makeover. , 2009, Molecular cell.

[15]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[16]  R. Elble.  Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[17]  M. Aminoff,et al.  Caffeine and Progression of Parkinson Disease , 2008, Clinical neuropharmacology.

[18]  L. Stefanis,et al.  α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.

[19]  S. Przedborski,et al.  Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. , 2005, Antioxidants & redox signaling.

[20]  M. Thun,et al.  Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. , 2004, American journal of epidemiology.

[21]  C. White,et al.  Downregulation of Protein Phosphatase 2A Carboxyl Methylation and Methyltransferase May Contribute to Alzheimer Disease Pathogenesis , 2004, Journal of neuropathology and experimental neurology.

[22]  M. Vila,et al.  MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease , 2004, Journal of bioenergetics and biomembranes.

[23]  G. Zeevalk,et al.  Adenosinergic Protection of Dopaminergic and GABAergic Neurons against Mitochondrial Inhibition through Receptors Located in the Substantia Nigra and Striatum, Respectively , 2003, The Journal of Neuroscience.

[24]  T. Park,et al.  Constitutive Induction of p-Erk1/2 Accompanied by Reduced Activities of Protein Phosphatases 1 and 2A and MKP3 Due to Reactive Oxygen Species during Cellular Senescence* , 2003, Journal of Biological Chemistry.

[25]  A. Rebollo,et al.  Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. , 2003, Biochimie.

[26]  Doyeun Kim,et al.  Extracellular and intracellular glutathione protects astrocytes from Zn2+-induced cell death , 2003, Neuroreport.

[27]  R. Rao,et al.  Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. , 2002, Biochemical and biophysical research communications.

[28]  E. Junn,et al.  Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.

[29]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[30]  M. Vila,et al.  The role of glial cells in Parkinson's disease , 2001, Current opinion in neurology.

[31]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[32]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[33]  V. Janssens,et al.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. , 2001, The Biochemical journal.

[34]  T. Shanley,et al.  The Serine/Threonine Phosphatase, PP2A: Endogenous Regulator of Inflammatory Cell Signaling1 , 2001, The Journal of Immunology.

[35]  S. Zołnierowicz.  Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. , 2000, Biochemical pharmacology.

[36]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[37]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[38]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[39]  R. Swerdlow,et al.  Mitochondrial dysfunction in idiopathic Parkinson disease. , 1998, American journal of human genetics.

[40]  C. Fall,et al.  Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.

[41]  I. Grants,et al.  Sublethal levels of oxidant stress stimulate multiple serine/threonine kinases and suppress protein phosphatases in Jurkat T cells. , 1995, Archives of biochemistry and biophysics.

[42]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[43]  P. Sonsalla,et al.  Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. , 1987, The Journal of pharmacology and experimental therapeutics.

[44]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[45]  E. Masliah,et al.  alpha-synuclein promotes mitochondrial deficit and oxidative stress. , 2000, The American journal of pathology.

[46]  S. Przedborski,et al.  Mechanisms of MPTP toxicity. , 1998, Movement disorders : official journal of the Movement Disorder Society.